30 results about "HPV Positive" patented technology

This invention relates to one polymer enzyme linkage reaction fluorescence test method to dialogue dangerous human body nipple shape virus and to isolate DNA sample HPV gene type to test one set of dangerous HPV infection from patient by the method, wherein, it belongs to life science and biological technique. This invention agent case comprises one fluorescence meter PCR technique as base of multi-layer polymer enzyme reaction composed of multiple HPV positive lead object, reaction lead object and fluorescence detector.

Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.

Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.

Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.

The invention relates to the field of gene therapy and discloses a fixed-point knockout system for high-risk HPV (human papilloma virus) E6E7 gene, namely targeted cutting of TALENs (transcription activator-like effector nucleases) of HPV E6E7 gene, wherein a TALENs expression vector of the target specific site is designed according to the high-risk HPV E6E7 gene sequence, and the HPV E6E7 gene sequence in the cells are cut in a targeted manner so as to knock out the target gene and induce the apoptosis increase and proliferation inhibition of corresponding subtype cells while the TALENs do not act on the HPV positive or HPV negative cells of other subtypes. By transfecting the TALEN expression vector in a subcutaneous tumor model of HPV positive cervical cancer cells, the growth of subcutaneous tumor can be obviously inhibited, and the tumor weight is reduced. According to the method for targeted knockout of high-risk HPV E6E7 gene using TALEN provided by the invention, the virus oncogene can be efficiently broken on the DNA level so as to cause apoptosis and proliferation inhibition of the HPV infected cells, and the method is of tremendous therapeutic value on HPV infection related diseases and particularly precancerous lesions such as cervical intraepithelial neoplasias.

The invention discloses a kit and method for methylation detection of cervical lesions and cervical cancer related gene. The kit contains reagents including a PCR reaction solution, eight primers fixed to a PCR octa-tube, a positive reference substance, a negative reference substance and a cell lysate for extracting a sample DNA. The detection method comprises the steps of extracting the sample DNA, processing and purifying the sample DNA, preparing a PCR reaction system and adding the sample, carrying out a PCR amplification reaction, collecting a fluorescence signal, obtaining and analyzingan amplification curve and a melting curve, obtaining a Ct value and a Tm value of each marker by analyzing the amplification curve and the melting curve, formulating a positive determination method based on a weighting algorithm, carrying out positive determination on each marker and integrating, finally explaining sample results. The kit has the advantages of high sensitivity, strong specificityand non-invasiveness, and is particularly suitable for auxiliary diagnosis of cervical high-grade lesions or cervical cancer and HPV-positive shunt management.

The invention relates to medicine for treating cervical erosion through HPV (human papillomavirus) positive-to-negative change. The medicine comprises the following ingredients in the contents (weight percentage): 30 percent to 40 percent of walnut peel, 10 percent to 15 percent of lithospermum, 5 percent to 10 percent of ramulus mori dust, 5 percent to 10 percent of golden cypress, 7 percent to 10 percent of radix sophorae flavescentis, 7 percent to 10 percent of fructus cnidii, 2 to 5 percent of methylcellulose, 2 to 5 percent of agar and 8 to 12 percent of acacia. The medicine has the advantages that the complete HPV positive-to-negative change can be realized, the cervical erosion is radically treated, simplicity is realized, the implementation is easy, high and low temperature is avoided, and the toxic or side effect on human bodies does not exist.

Relating to the field of gene therapy, the invention provides a method for knockout of a high-risk human papillomavirus (HPV) E6E7 gene by zinc finger nucleases (ZFNs). According to a high-risk type HPV E6E7 gene sequence, the method designs ZFNs expression vectors of a targeted specific site to targetedly cut the HPVE6E7 gene sequence in cells, thereby knocking out a target gene. In corresponding subtype HPV infected cells, the ZFNs can significantly induce cell apoptosis and proliferation inhibition, and has no effect on other subtype HPV positive cells and HPV negative cells. Transfection of the ZFNs expression vectors in a subcutaneous tumor model of HPV positive cervical cancer cells can obviously inhibit the growth rate of subcutaneous tumors and alleviate tumors. The method for targeted knockout of the high-risk HPV E6E7 gene by ZFNs can efficiently destroy virus oncogenes at the DNA level so as to make HPV infected cells undergo apoptosis and proliferation inhibition, and has enormous treatment value to HPV infection related diseases, especially cervical intraepithelial neoplasias and other precancerous lesions.

The inventors now have developed a (molecular) diagnostic assay based on detection of alterations in markers MAL and hsa-mi R124, in particular promoter hypermethylation, to identify human papillomavirus (HPV)-induced high-grade precancerous lesions such as premalignant cervical lesions of invasive cervical cancer, within cell material obtained via self-sampling. In particular, the present invention relates to the use of the MAL gene (including its promoter) and the hsa-mi R124 gene as marker for HPV-induced high-grade premalignant lesions, allowing early detection and a better treatment option for the individual patient.

The inventors now have developed a (molecular) diagnostic assay based on detection of alterations in markers MAL and hsa-mi R124, in particular promoter hypermethylation, to identify human papillomavirus (HPV)-induced high-grade precancerous lesions such as premalignant cervical lesions of invasive cervical cancer, within cell material obtained via self- sampling. In particular, the present invention relates to the use of the MAL gene (including its promoter) and the hsa-mi R124 gene as marker for HPV- induced high-grade premalignant lesions, allowing early detection and a better treatment option for the individual patient.

The invention discloses a plasma exosome protein Mortalin taken as an HPV positive cervical cancer diagnosis marker and an application thereof. Differential proteins of plasma exosomes of a cervical cancer tumor group patient, a precancerous lesion patient (CIN) and a healthy person are compared through proteomics, the mortalin expression condition after the HPV key molecule HPVE6 / E7 is knocked out is further determined, that exosome mortalin can serve as a molecular marker of cervical cancer is found, preliminary screening of cervical cancer can be conducted when plasma exosome mortalin is detected, and the early definite diagnosis probability of the cervical cancer can be increased.

Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.

Compositions and methods of treatment are provided for preventing cancers caused by high-risk human papilloma viruses (HPV). Cancers amenable to prevention include cervical cancer, head cancers, neck cancers, and oral cancers. The compositions block interaction between HPV 16 E6, one of two major viral oncogenes, and its partners, thereby resensitizing HPV positive cells to apoptosis.

The invention belongs to the field of bio-medicines, and specifically relates to an HPV (Human Papillomavirus) L1 recombinant annulet DNA immunoglobulin of yolk (IgY) and application thereof in preparing a drug for preventing / treating HPV infection. The HPV L1 recombinant annulet DNA comprises an L1 gene segment of HPV16 and a signal peptide sequence, and is taken as a nucleic acid antigen for directly immunizing a laying hen to obtain the IgY. Bio-activity of the IgY obtained by intramuscular injection of the DNA nucleic acid antigen for immunizing the laying hen is much higher than that of the IgY prepared by a common technology (subcutaneous injection of the protein antigen), valence of an antibody is higher, and specificity is stronger. The IgY can be used for preparing the drug for preventing / treating the HPV infection; a vagina drug inputs the high-activity anti-HPV antibody to a HPV positive patient, and a nano-liposome method is combined, so that the antibody gets across the film to enter into cells to directly neutralize HPV viruses in the cells. The IgY is of great significance for preventing cervical cancer.

The invention relates to the technical field of disease treatment, in particular to a technology for treating HPV (human papillomavirus) infected patients, which improves the cure rate of HPV positive patients. The NK cell adoptive immunotherapy is applied to control and treatment of HPV positive patients.

The present invention relates to HPV-positive as well as HPV-negative screening platforms that are highly serum-dependent, for use as HNSCC models. These HNSCC models die reproducibly in serum-deprived conditions and the introduction of driver mutations (or increased levels of the WT gene) confers enhanced cell survival and proliferation under serum deprivation. These platforms have the major advantages of allowing functional screening of mutations in relevant HNSCC models (HPV-positive and HPV-negative). In addition to oncogene screening, this model can also be used in drug discovery. Specifically, cells expressing mutations that confer increased survival can then be screened against panels of therapeutic agents to determine if the mutation(s) can predict the optimal treatment for patients whose tumors harbor the mutation(s).

The invention discloses a CRISPR / Lbcpf1 gene editing system and an application thereof, belongs to the field of bioengineering and biomedicine, and relates to early prevention and treatment of cervical lesions. The CRISPR / Lbcpf1 gene editing system provided by the invention comprises crRNA expression plasmids and Lbcpf1 expression plasmids, the crRNA expression plasmids and the Lbcpf1 expression plasmids are co-transfected into cells to express and form an Lbcpf1-crRNA binary complex, and the recognition and shearing of an HMGA2 gene can be realized, so that the function of the gene is lost; the CRISPR / Lbcpf1 gene editing system can specifically cause apoptosis of HPV positive cervical lesion cells, and can be used as a gene therapy drug for effectively treating HPV positive cervical lesion.

The invention discloses an external medicine capable of resisting HPV infection and converting HPV positive to HPV negative and a preparation method thereof. The external medicine is prepared from the following raw materials in parts by weight: 20 to 50 parts of hedgehog fat, 10 to 30 parts of frankincense, 10 to 20 parts of radix angelicae, 10 to 20 parts of radix ranunculi ternati, 5 to 15 parts of radix et rhizoma rhei, 5 to 10 parts of airpotato yam rhizome, 5 to 10 parts of dried alum and 2 to 5 parts of realgar. Years of clinical experience prove that the medicine disclosed by the invention has no adverse reaction, the medicine can avoid the first-pass effect of the liver when being externally used, has a targeting effect, and has a higher inhibition rate on host cytopathy caused by HPV than that of immune preparations and interferon.

The invention relates to traditional Chinese medicine compositions, and particularly discloses a traditional Chinese medicine composition for treating human papilloma virus (HPV) infection and a preparing method and application thereof. Effective components of the traditional Chinese medicine composition are derived from sinopodophyllum hexandrum, cortex magnoliae officinalis, rhizoma polygoni cuspidati, air-plant herb, liquorice root, fructus kochiae, fructus bruceae, rhizoma smilacis glabrae and herba centellae. The traditional Chinese medicine composition is combined with the clinical treatment effect and condyloma acuminate animal model tests to constantly adjust the use quantities of all active pharmaceutical ingredients in the formula, and full play is given to the compatibility andsynthesis effects of all the active pharmaceutical ingredients in the traditional Chinese medicine prescription. The traditional Chinese medicine composition can effectively remove the human papillomavirus, has a significant treatment effect on HPV low-risk infection and HR-HPV positive cervical intraepithelial neoplasia low-grade lesions, and can increase the number of langerhans cells, and thusthe immunity of the body is enhanced.

The invention discloses a marker (MYC) for predicting the cervical lesions occurrence of HPV positive patients. The biomarker is an MYC gene or protein encoded by the MYC gene, and the amino acid sequence of the biomarker is shown as SEQ NO.1. The biomarker has an HPV integration site. The biomarker can assist doctors in diagnosing the cervix uteri high-grade intraepithelial neoplasia conditions of the human papilloma virus positive patients or screen out precancerous lesions patients with the risk of the progress to the cervical cancer for emphatic monitoring. The biomarker which detects thehigh risk group of the human papilloma virus positive patients has the advantages of being rapid, accurate, convenient to use, low in false positive rate and the like and has important clinical diagnosis significance.

The present invention relates to the field of gene therapy, and provides a method for knocking out the high-risk human papillomavirus (Human papillomavirus, HPV) E6E7 gene by using zinc finger nuclease, which is based on the high-risk HPV E6E7 gene sequence, and designs a targeting specific site The ZFNs expression vector of ZFNs targets the HPV E6E7 gene sequence in cells, and then knocks out the target gene, which can obviously induce apoptosis and inhibit proliferation in cells infected with the corresponding subtype of HPV, while positive for other subtypes of HPV Cells and HPV-negative cells had no effect. Transfection of ZFNs expression vector in the subcutaneous tumor model of HPV-positive cervical cancer cells can significantly inhibit the growth rate of subcutaneous tumors and reduce tumor weight. The method of knocking out the high-risk HPV E6E7 gene by using zinc finger ribozyme can effectively destroy the viral oncogene at the DNA level, and cause apoptosis and proliferation inhibition of HPV-infected cells. Precancerous lesions such as internal neoplasia have great therapeutic value.

The invention relates to the field of gene therapy and discloses a fixed-point knockout system for high-risk HPV (human papilloma virus) E6E7 gene, namely targeted cutting of TALENs (transcription activator-like effector nucleases) of HPV E6E7 gene, wherein a TALENs expression vector of the target specific site is designed according to the high-risk HPV E6E7 gene sequence, and the HPV E6E7 gene sequence in the cells are cut in a targeted manner so as to knock out the target gene and induce the apoptosis increase and proliferation inhibition of corresponding subtype cells while the TALENs do not act on the HPV positive or HPV negative cells of other subtypes. By transfecting the TALEN expression vector in a subcutaneous tumor model of HPV positive cervical cancer cells, the growth of subcutaneous tumor can be obviously inhibited, and the tumor weight is reduced. According to the method for targeted knockout of high-risk HPV E6E7 gene using TALEN provided by the invention, the virus oncogene can be efficiently broken on the DNA level so as to cause apoptosis and proliferation inhibition of the HPV infected cells, and the method is of tremendous therapeutic value on HPV infection related diseases and particularly precancerous lesions such as cervical intraepithelial neoplasias.

The invention discloses the technical field of gynecologic products and particularly relates to the field of HPV positive-to-negative spray. The HPV positive-to-negative spray is prepared from the following components in parts by weight: 30 to 40 parts of a blueberry leaf extract, 27 to 37 parts of herba patriniae, 25 to 35 parts of triethanol, 25 to 35 parts of chrysanthemum indicum, 25 to 35 parts of callicarpa nudiflora, 18 to 28 parts of radix lithospermi, 18 to 28 parts of polygonum tinctorium, 15 to 25 parts of curcuma zedoary, 15 to 25 parts of rhizoma coptidis, 14 to 24 parts of flos lonicerae, 8 to 18 parts of fructus cnidii, 5 to 15 parts of herba houttuyniae and the balance of normal saline. The HPV positive-to-negative spray disclosed by the invention selects traditional Chinese medicines as raw materials and has the advantages of easiness in raw material obtaining, reasonable formula, small toxic and / or side effects and high rate of HPV positive-to-negative; by using the HPV positive-to-negative spray, the efficacies of clearing away heat and toxic materials, and resisting bacteria, inflammation and viruses are realized, an HPV virus is effectively inhibited and HPV positive-to-negative conversion is realized.

The invention belongs to the technical field of medical treatment, and discloses application of miRNA 21 in preparation of a reagent for judging the radiotherapy prognosis survival rate of a head and neck squamous cell carcinoma patient infected by HPV. The reagent is used for quantitatively detecting the expression quantity of the miRNA 21. By detecting the expression conditions of HPV E6 / E7 mRNA and candidate ray sensitivity related miRNA in HPV positive head and neck tumor tissues before radiotherapy and through single-factor and multi-factor regression analysis, it is obtained that the HPV E6 / E7 mRNA and host miRNA 21 are co-expressed as independent prognosis factors influencing the head and neck tumors, and the HPV E6 / E7 mRNA and host miRNA 21 can be used for radiotherapy prognosis judgment of HPV infection positive head and neck tumor patients in China, reference is provided for making an individualized treatment scheme of the head and neck tumor, and finally the purpose of reducing the death rate of the head and neck tumor is achieved.

The invention belongs to the technical field of biology, and particularly relates to a reagent kit for detecting 14 high-risk HPV subtypes, and a detection method. The reagent kit for detecting 14 high-risk HPV subtypes comprises HPV reaction liquid, HPV positive control and HPV negative control, wherein the HPV reaction liquid consists of primers and PCR buffer liquid, the HPV positive control isplasmid DNA, and the HPV negative control is wild type human genome DNA. The detection method is high in detection speed, the whole detection process including an extraction step only needs 150min, besides, the detection method has the characteristics of being good in specificity, low in price, high in accuracy and simple to operate, and actual requirements for clinical fast detection can be completely met.

The invention provides a caffeic acid phenethyl ester as a medicine for resisting cervical cancer. The invention provides application of caffeic acid phenethyl ester as an E6AP / p53 compound inhibitor and an inhibitor for ubiquitination degradation of p53. Experimental research shows that in a cell experiment, CAPE can inhibit the interaction between E6AP and p53 in an HR-HPV positive cervical cancer cell line, reduce the ubiquitination modification level of p53, prolong the half-life period of p53 and increase the level of p53.

The invention relates to medicine for treating cervical erosion through HPV (human papillomavirus) positive-to-negative change. The medicine comprises the following ingredients in the contents (weight percentage): 30 percent to 40 percent of walnut peel, 10 percent to 15 percent of lithospermum, 5 percent to 10 percent of ramulus mori dust, 5 percent to 10 percent of golden cypress, 7 percent to 10 percent of radix sophorae flavescentis, 7 percent to 10 percent of fructus cnidii, 2 to 5 percent of methylcellulose, 2 to 5 percent of agar and 8 to 12 percent of acacia. The medicine has the advantages that the complete HPV positive-to-negative change can be realized, the cervical erosion is radically treated, simplicity is realized, the implementation is easy, high and low temperature is avoided, and the toxic or side effect on human bodies does not exist.

The present invention relates to HPV-positive as well as HPV-negative screening platforms that are highly serum-dependent, for use as HNSCC models. These HNSCC models die reproducibly in serum-deprived conditions and the introduction of driver mutations (or increased levels of the WT gene) confers enhanced cell survival and proliferation under serum deprivation. These platforms have the major advantages of allowing functional screening of mutations in relevant HNSCC models (HPV-positive and HPV-negative). In addition to oncogene screening, this model can also be used in drug discovery. Specifically, cells expressing mutations that confer increased survival can then be screened against panels of therapeutic agents to determine if the mutation(s) can predict the optimal treatment for patients whose tumors harbor the mutation(s).

The invention discloses a marker for predicting the occurrence of cervical lesions of HPV (human papilloma virus)-positive patients. The marker is a TP63 gene or a protein encoded thereby, the amino acid sequence of the marker is represented by SEQ NO. 1, and the biomarker has an HPV integration site. The biomarker can assist in the diagnosis of cervical high-grade intraepithelial neoplasia of theHPV-positive patients, or screening of people groups suffering from precancerous lesions and having a risk of developing cervical cancers for focused monitoring. The marker for detecting high-risk populations of the HPV-positive patients has the advantages of rapidness, accuracy, convenience, low false positive rate and the like, and has important significance in clinical diagnosis.